Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin

International Journal of Biochemistry and Cell Biology

Volumn 37, Issue 1, 2005, Pages 142-154

  Rozanov, Dmitri V ^a   Golubkov, Vladislav S ^a   Strongin, Alex Y ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

DMEM; Dulbecco's MEM; edema factor; EF; FP59; fusion protein 59 (a chimera in which LF residues 1 254 have been fused with the ADP ribosylation domain III of Pseudomonas exotoxin A); lethal factor; LF; lysis buffer

Indexed keywords

AB 815; ANTHRAX TOXIN; ANTIGEN; DECANOYLARGINYLVALYLLYSYLARGINYL CHLOROMETHYL KETONE; GLUTAMIC ACID; GLUTAMINE; ILOMASTAT; LEUCINE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MON 152; MONOCLONAL ANTIBODY; PROTECTIVE AGENT; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL FREE SYSTEM; CELL LINE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CELL LINE, TUMOR; EXOTOXINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

ANTHRAX; PSEUDOMONAS;

EID: 4644371786     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.06.005     Document Type: Article

References (59)

1. Abrami L., Liu S., Cosson P., Leppla S.H., van der Goot F.G. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. Journal of Cell Biology. 160:2003;321-328
2. Annabi B., Lachambre M., Bousquet-Gagnon N., Page M., Gingras D., Beliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochemical Journal. 353:2001;547-553
3. Baciu P.C., Suleiman E.A., Deryugina E.I., Strongin A.Y. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alpha(v) integrin regulates cross-talk between alpha(v) beta(3) and alpha(2) beta(1) integrinsin breast carcinoma cells. Experimental Cell Research. 291:2003;167-175
4. Bardwell A.J., Abdollahi M., Bardwell L. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. Biochemical Journal. 378:2004;569-577
5. Beauregard K.E., Collier R.J., Swanson J.A. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiology. 2:2000;251-258
6. Belien A.T., Paganetti P.A., Schwab M.E. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. Journal of Cell Biology. 144:1999;373-384
7. Belkin A.M., Akimov S.S., Zaritskaya L.S., Ratnikov B.I., Deryugina E.I., Strongin A.Y. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. The Journal of Biological Chemistry. 276:2001;18415-18422
8. Bhatnagar R., Batra S. Anthrax toxin. Critical Reviews in Microbiology. 27:2001;167-200
9. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature. 414:2001;225-229
10. Bradley K.A., Young J.A. Anthrax toxin receptor proteins. Biochemical Pharmacology. 65:2003;309-314
11. Bradley K.A., Mogridge J., Rainey G.J., Batty S., Young J.A. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. The Journal of Biological Chemistry. 278:2003;49342-49347
12. Chauhan V., Bhatnagar R. Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor. Infection and Immunity. 70:2002;4477-4484
13. Chopra A.P., Boone S.A., Liang X., Duesbery N.S. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. The Journal of Biological Chemistry. 278:2003;9402-9406
14. Collier R.J., Young J.A. Anthrax toxin. Annual Review of Cell and Developmental Biology. 19:2003;45-70
15. Deryugina E.I., Ratnikov B., Monosov E., Postnova T.I., DiScipio R., Smith J.W., et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Experimental Cell Research. 263:2001;209-223
16. Deryugina E.I., Ratnikov B.I., Postnova T.I., Rozanov D.V., Strongin A.Y. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. The Journal of Biological Chemistry. 277:2002a;9749-9756
17. Deryugina E.I., Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Research. 62:2002b;580-588
18. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:1998;734-737
19. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer. 2:2002;161-174
20. Frankel A.E., Koo H.M., Leppla S.H., Duesbery N.S., Wounde G.F. Novel protein targeted therapy of metastatic melanoma. Current Pharmaceutical Design. 9:2003;2060-2066
21. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infection and Immunity. 63:1995;82-87
22. Habelhah H., Okada F., Kobayashi M., Nakai K., Choi S., Hamada J., et al. Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression. Oncogene. 18:1999;1771-1776
23. Hornebeck W., Emonard H., Monboisse J.C., Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Seminars in Cancer Biology. 12:2002;231-241
24. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 114:2003;33-45
25. Jiang A., Lehti K., Wang X., Weiss S.J., Keski-Oja J., Pei D. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;13693-13698
26. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. Journal of Cell Biology. 153:2001;893-904
27. Koo H.M., VanBrocklin M., McWilliams M.J., Leppla S.H., Duesbery N.S., Woude G.F. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;3052-3057
28. Kridel S.J., Sawai H., Ratnikov B.I., Chen E.I., Li W., Godzik A., et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. The Journal of Biological Chemistry. 277:2002;23788-23793
29. Leppla S.H. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proceedings of the National Academy of Sciences of the United States of America. 79:1982;3162-3166
30. Liu S., Netzel-Arnett S., Birkedal-Hansen H., Leppla S.H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Research. 60:2000;6061-6067
31. Liu S., Bugge T.H., Leppla S.H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. The Journal of Biological Chemistry. 276:2001;17976-17984
32. Liu S., Leppla S.H. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. The Journal of Biological Chemistry. 278:2003;5227-5234
33. Liu S., Schubert R.L., Bugge T.H., Leppla S.H. Anthrax toxin: Structures, functions and tumour targeting. Expert Opinion on Biological Therapy. 3:2003a;843-853
34. Liu S., Aaronson H., Mitola D.J., Leppla S.H., Bugge T.H. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proceedings of the National Academy of Sciences of the United States of America. 100:2003b;657-662
35. Maquoi E., Noel A., Frankenne F., Angliker H., Murphy G., Foidart J.M. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Letters. 424:1998;262-266
36. Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. The Journal of Biological Chemistry. 269:1994;20607-20612
37. Moayeri M., Haines D., Young H.A., Leppla S.H. Bacillus anthracis lethal toxin induces TNFa-independent hypoxia-mediated toxicity in mice. Journal of Clinical Investigation. 112:2003;670-682
38. Mock M., Fouet A. Anthrax. Annual Review of Microbiology. 55:2001;647-671
39. Mock M., Mignot T. Anthrax toxins and the host: A story of intimacy. Cell Microbiology. 5:2003;15-23
40. Nabeshima K., Inoue T., Shimao Y., Okada Y., Itoh Y., Seiki M., et al. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Research. 60:2000;3364-3369
41. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. The Journal of Biological Chemistry. 274:1999;21491-21494
42. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nature Reviews Cancer. 2:2002;657-672
43. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:1995;244-247
44. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature. 385:1997;833-838
45. Prince A.S. The host response to anthrax lethal toxin: Unexpected observations. The Journal of Clinical Investigation. 112:2003;656-658
46. Ratnikov B., Deryugina E., Leng J., Marchenko G., Dembrow D., Strongin A. Determination of matrix metalloproteinase activity using biotinylated gelatin. Analytical Biochemistry. 286:2000;149-155
47. Remacle A., Murphy G., Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. Journal of Cell Science. 116:2003;3905-3916
48. Rozanov D.V., Deryugina E.I., Ratnikov B.I., Monosov E.Z., Marchenko G.N., Quigley J.P., et al. Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. The Journal of Biological Chemistry. 276:2001;25705-25714
49. Rozanov D.V., Strongin A.Y. Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. The Journal of Biological Chemistry. 278:2003;8257-8260
50. Rozanov D.V., Deryugina E.I., Monosov E.Z., Marchenko N.D., Strongin A.Y. Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Experimental Cell Research. 293:2004;81-95
51. Scobie H.M., Rainey G.J., Bradley K.A., Young J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proceedings of the National Academy of Sciences of the United States of America. 100:2003;5170-5174
52. Seiki M. Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Letters. 194:2003;1-11
53. Seiki M., Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Science. 94:2003;569-574
54. Singh Y., Klimpel K.R., Goel S., Swain P.K., Leppla S.H. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infection and Immunity. 67:1999;1853-1859
55. Strongin A.Y., Marmer B.L., Grant G.A., Goldberg G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. The Journal of Biological Chemistry. 268:1993;14033-14039
56. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. The Journal of Biological Chemistry. 270:1995;5331-5338
57. Takahashi S., Nakagawa T., Kasai K., Banno T., Duguay S.J., Van de Ven W.J., et al. LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. The Journal of Biological Chemistry. 270:1995;26565-26569
58. Varughese M., Chi A., Teixeira A.V., Nicholls P.J., Keith J.M., Leppla S.H. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Molecular Medicine. 4:1998;87-95
59. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 19:2000;6642-6650